Chemical Biology & Drug Design

Scope & Guideline

Elevating the standards of biochemistry and drug development.

Introduction

Welcome to your portal for understanding Chemical Biology & Drug Design, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1747-0277
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2006 to 2024
AbbreviationCHEM BIOL DRUG DES / Chem. Biol. Drug Des.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal "Chemical Biology & Drug Design" focuses on the integration of chemical biology and medicinal chemistry to develop new therapeutic agents and understand their mechanisms of action. It aims to bridge the gap between chemistry and biology, emphasizing innovative drug design, synthesis, and evaluation methodologies.
  1. Medicinal Chemistry:
    The journal emphasizes the design and synthesis of novel chemical compounds with potential therapeutic applications, particularly in cancer, infectious diseases, and chronic conditions.
  2. Chemical Biology:
    Research that explores the interactions between biological systems and chemical entities, including the mechanisms behind drug action and biological pathways.
  3. Drug Development and Design:
    The journal features works related to the development of new drugs, including formulation strategies, delivery systems, and efficacy evaluations.
  4. Network Pharmacology:
    A focus on understanding the multi-target interactions of drugs within biological networks, which is essential for elucidating complex disease mechanisms.
  5. In Silico Studies:
    Emphasizes computational approaches in drug discovery, including molecular docking, QSAR modeling, and machine learning applications to predict biological activity.
  6. Natural Products Chemistry:
    Explores the therapeutic potential of natural compounds and their derivatives, focusing on their isolation, structural elucidation, and biological activities.
Recent publications in "Chemical Biology & Drug Design" indicate a shift towards innovative and interdisciplinary approaches in drug discovery and development. The following themes have emerged as significant focuses of research.
  1. Targeted Cancer Therapies:
    An increasing number of studies are focusing on targeted therapies that leverage specific molecular pathways in cancer treatment, reflecting the growing understanding of tumor biology.
  2. Combination Therapies:
    Research is trending towards exploring the efficacy of combination therapies that utilize multiple agents to enhance therapeutic outcomes and overcome resistance mechanisms.
  3. Biologics and Biopharmaceuticals:
    The emergence of biologics as therapeutic agents, including monoclonal antibodies and protein-based drugs, is gaining traction, emphasizing the need for advanced drug design techniques.
  4. Machine Learning and AI in Drug Discovery:
    The integration of machine learning and artificial intelligence into drug discovery processes is becoming increasingly prominent, aiding in predictive modeling and optimization of drug candidates.
  5. Natural Product Derivatives:
    There is a growing interest in the modification of natural products to enhance their pharmacological properties, with a focus on their potential as leads for new drug development.
  6. Nanotechnology in Drug Delivery:
    Research is increasingly focusing on the application of nanotechnology for drug delivery systems, enhancing the bioavailability and targeting of therapeutic agents.

Declining or Waning

While the journal maintains a robust focus on various emerging themes, certain areas have seen a decline in prominence over recent years. This may reflect shifts in research priorities or advancements in specific methodologies.
  1. Traditional Antimicrobial Agents:
    Research focusing on conventional antibiotics and their mechanisms has become less prevalent as the field moves towards exploring novel and multi-targeted therapeutic strategies.
  2. Single-Target Drug Design:
    There is a noticeable decrease in studies centered around single-target drugs, as the complexity of diseases has led to a shift towards multi-target approaches and combination therapies.
  3. In vitro Only Studies:
    Research that solely relies on in vitro models without in vivo validation has waned, as the scientific community increasingly emphasizes the importance of comprehensive in vivo studies to support findings.
  4. Synthetic Methods with Limited Applicability:
    The use of traditional synthetic methods without innovative adaptations or applications in drug design has seen a decline, as researchers seek more versatile and efficient synthetic strategies.

Similar Journals

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Innovating Drug Development Through Cutting-Edge Research.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0223-5234Frequency: 18 issues/year

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

Future Medicinal Chemistry

Advancing the frontiers of drug discovery.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

RSC Medicinal Chemistry

Innovative Research for Tomorrow's Therapeutics
Publisher: ROYAL SOC CHEMISTRYISSN: Frequency: 12 issues/year

RSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.

European Journal of Medicinal Chemistry Reports

Fostering collaboration for groundbreaking medicinal advancements.
Publisher: ELSEVIERISSN: 2772-4174Frequency: 3 issues/year

European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

Journal of Natural Medicines

Advancing Knowledge in Complementary and Alternative Medicine
Publisher: SPRINGER JAPAN KKISSN: 1340-3443Frequency: 4 issues/year

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

Anti-Cancer Agents in Medicinal Chemistry

Bridging medicinal chemistry and clinical applications for a cancer-free future.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

MEDICINAL RESEARCH REVIEWS

Transforming Research into Revolutionary Therapeutics
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

MOLECULAR DIVERSITY

Fostering Excellence in Molecular Research Since 1995
Publisher: SPRINGERISSN: 1381-1991Frequency: 4 issues/year

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

Open Chemistry

Illuminating the Path of Chemical Innovation
Publisher: DE GRUYTER POLAND SP Z O OISSN: 2391-5420Frequency: 1 issue/year

Open Chemistry, published by DE GRUYTER POLAND SP Z O O, is a distinguished peer-reviewed journal that has been serving the global chemistry community since its inception. With an ISSN of 2391-5420 and an E-ISSN also of 2391-5420, this open-access journal has been accessible to researchers and practitioners alike since 2015, ensuring a wide dissemination of high-quality research findings. Located in Germany, specifically at BOGUMILA ZUGA 32A STR, 01-811 WARSAW, MAZOVIA, POLAND, Open Chemistry aims to publish innovative research across various chemical disciplines, with special attention to miscellaneous chemistry and materials chemistry. It is currently ranked in the Q3 category for both fields as of 2023, reflecting its solid standing within the academic community, with specific ranks of 187/408 in General Chemistry and 153/317 in Materials Chemistry, corresponding to respective percentiles of 54 and 51. Open Chemistry not only enhances the accessibility of cutting-edge research but also serves as a vital resource for students, professionals, and scholars seeking to advance their knowledge in the rapidly evolving landscape of chemical sciences.

SAR AND QSAR IN ENVIRONMENTAL RESEARCH

Transforming Data into Sustainable Solutions.
Publisher: TAYLOR & FRANCIS LTDISSN: 1062-936XFrequency: 12 issues/year

SAR and QSAR in Environmental Research is a leading journal published by Taylor & Francis Ltd, focusing on the integration of Structure-Activity Relationships (SAR) and Quantitative Structure-Activity Relationships (QSAR) within the realm of environmental science. Since its inception in 1993, the journal has been a pivotal platform for disseminating innovative research that bridges the gap between chemistry and environmental sustainability, ranking in the Q3 quartile for Bioengineering, Drug Discovery, and miscellaneous Medicine categories as of 2023. Featuring a compelling collection of peer-reviewed articles, it caters to academic and professional audiences seeking to enhance their understanding of molecular interactions and their implications for environmental health. Although the journal does not currently offer Open Access options, its rigorous editorial standards ensure high-quality, impactful publications that are crucial for advancing methodologies in pharmacology, toxicology, and bioengineering. With an ISSN of 1062-936X and an E-ISSN of 1029-046X, SAR and QSAR in Environmental Research continues to serve as an essential resource for researchers, academics, and practitioners dedicated to innovative approaches in environmental research.